Navigation Links
HEI, Inc. Closes on Sale of RFID Division Assets
Date:9/4/2007

Chanhassen, MN 55317

FORWARD LOOKING INFORMATION

Information in this news release, which is not historical, includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements contained in this press release, including the integration of the Advanced Medical Division, the implementation of business strategies, growth of specific markets, improved results and the estimated HEI revenue, cash flow and profits, are forward looking statements. All of such forward-looking statements involve risks and uncertainties including, without limitation, continuing adverse business and market conditions, the ability of HEI to secure and satisfy customers, the availability and cost of materials from HEI's suppliers, our ability to satisfy financial or other obligations or covenants set forth in our financing agreements, adverse competitive developments, change in or cancellation of customer requirements, collection of receivables and outstanding debt, HEI's ability to control fixed and variable operating expenses. , and other risks detailed from time to time in HEI's SEC filings. We undertake no obligation to update these statements to reflect ensuing events or circumstances, or subsequent actual results. See the risk factor section in annual report on Form 10K for year ended September 2, 2006.


'/>"/>
SOURCE HEI, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Russia warns against travel to Turkey, Iran closes border
2. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
3. SKorean Online Dogmeat Retailer Closes Site Amid Uproar
4. Sugar Helps Control Cell Division
5. Researchers Reverse Cell Division
6. Division Among Delegates To Dilute UNs AIDS Plans: Activists
7. United Biotech Launches New Oncology Division
8. Understanding HIV Interference With Infected Cell Division
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 2Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 3Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 4Health News:Feeding America and Abbott Partner For Hurricane Relief 2Health News:Feeding America and Abbott Partner For Hurricane Relief 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 2Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 4Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 5Health News:Pain Medicine Experts Recommend Monitoring, Education for All Opioid Medicines 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 3Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 2Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 3
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 1Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 2Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 3Insect resistance to Bt crops can be predicted monitored and managed 61927 1Insect resistance to Bt crops can be predicted monitored and managed 61927 2Research and legislation should go hand in hand as much as possible 10861 1Research and legislation should go hand in hand as much as possible 10861 2